Regeneron to begin trials for COVID-19 antibody cocktail

Regeneron will conduct placebo-controlled trials of REGN-COV2 at multiple sites in four different populations: hospitalized COVID-19 patients, non-hospitalized patients with COVID-19 symptoms, uninfected people in high-risk groups such as healthcare workers, and uninfected people in close contact with infected patients. The first two trials will focus on virologic, safety, and clinical end points in hospitalized and non-hospitalized patients.